
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc. demonstrates a solid outlook due to a significant increase in Chromium reaction volumes, indicating strong market resilience despite ongoing pricing pressures. The company is projected to see substantial growth in consumables, with estimates ranging from 5 to 19 times per platform by the year 2027, outpacing instrument revenue growth. This robust demand for consumables suggests sustained relevance and a competitive edge in the life sciences technology sector amid challenges in pharmaceutical spending.
Bears say
10x Genomics Inc has experienced significant contraction, with a decline in revenues attributed to double-digit pricing pressure and flat to modestly lower volumes, with growth not expected to resume until 2027. The company reported an EPS miss of -$0.40 compared to the expected -$0.30 for the fourth quarter, alongside a full-year revenue outlook that fell below expectations. Additionally, despite market expansion since the peak stock prices in 2021, the growth has not met analysts' expectations, leading to a stock price decline of over 90% since that peak.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares